Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	6.38B
Revenue (ttm)	272.88M
Net Income (ttm)	-606.04M
Shares Out	118.50M
EPS (ttm)	-5.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,440,285
Open	50.52
Previous Close	50.30
Day's Range	50.52 - 54.96
52-Week Range	19.83 - 94.75
Beta	0.97
Analysts	Strong Buy
Price Target	71.00 (+31.8%)
Earnings Date	Nov 1, 2023

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 767
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS

Financial Performance

In 2022, APLS's revenue was $75.42 million, an increase of 13.31% compared to the previous year's $66.56 million. Losses were -$652.17 million, -12.62% less than in 2021.

Analyst Forecast

According to 16 analysts, the average rating for APLS stock is "Strong Buy." The 12-month stock price forecast is $71.0, which is an increase of 31.80% from the latest price.

Price Target

$71.0

(31.80% upside)

Analyst Consensus: Strong Buy